Login

Financial Snapshot

Revenue
TTM
$3.954M
Gross Margin
TTM
58.79%
Net Income
TTM
-$8.484M
Current Assets
2025 Q4
$15.63M
Current Liabilities
2025 Q4
$3.444M
Current Ratio
2025 Q4
453.86%
Total Assets
2025 Q4
$20.05M
Total Liabilities
2025 Q4
$20.13M
Book Value
2025 Q4
-82.00K
Cash
2025 Q4
$12.96M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$13.64M

Stock Price

Loading...
Market Cap: $7.1424 Million

About Evogene Ltd

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 142 full-time employees. The company went IPO on 2007-06-11. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Industry: Agricultural Chemicals Peers: Chemomab Therapeutics Ltd Enlivex Ltd Collplant Biotechnologies Ltd Protalix Biotherapeutics Inc Entera Bio Ltd.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support